-
The CDC has recommended vaccination for flu in individuals six
months of age and older. The flu vaccine is developed annually
targeted against the most active flu strains predictive for the
season. However, other factors including a patient's weak immune
system response, exposure to non-covered flu strains and other
infectious agents including, but not limited to, Mycoplasma
pneumoniae, adenovirus, respiratory syncytial virus,
rhinovirus and parainfluenza virus may cause flu or flu-like
symptoms following exposure.
Read More
-
The CDC has recommended vaccination for flu in individuals six
months of age and older. The flu vaccine is developed annually
targeted against the most active flu strains predictive for the
season. However, other factors including a patient's weak immune
system response, exposure to non-covered flu strains and other
infectious agents including, but not limited to, Mycoplasma
pneumoniae, adenovirus, respiratory syncytial virus,
rhinovirus and parainfluenza virus may cause flu or flu-like
symptoms following exposure.
Read More
-
The CDC has recommended vaccination for flu in individuals six
months of age and older. The flu vaccine is developed annually
targeted against the most active flu strains predictive for the
season. However, other factors including a patient's weak immune
system response, exposure to non-covered flu strains and other
infectious agents including, but not limited to, Mycoplasma
pneumoniae, adenovirus, respiratory syncytial virus,
rhinovirus and parainfluenza virus may cause flu or flu-like
symptoms following exposure.
Read More
-
Solstas Lab Partners is pleased to announce the addition of the
COBASAmpliPrep/COBAS TaqMan HCV Test, v2.0 and the Abbott Molecular
RealTime HCV Genotype II assay to our testing menu. Both of these
additions are FDA approved and intended for use as an aid in the
management of HCV-infected individuals and will be enhancements to
the existing HCV viral load and genotyping assays currently
performed...
Read
More
-
Solstas Lab Partners is pleased to announce the addition of a
new Rheumatoid Arthritis Screening Profile to our menu. This
profile includes four tests which Solstas Lab Partners currently
offers individually, in response to the recommendations of the
American College of Rheumatology (ACR) for Rheumatoid Arthritis
screening (1). The goal of earlier screening for Rheumatoid
Arthritis (RA) is to prevent patients from developing the chronic,
erosive disease state with earlier treatment. Certain laboratory
tests can precede the clinical manifestation of RA by many
years....
Read More
-
Solstas Lab Partners is pleased to announce that we have aligned
with PhenoPath Laboratories, a national reference pathology
laboratory, to provide your practice with one solution for both
your clinical and cancer diagnostic testing needs....
Read More
-
As with any type of laboratory specimen, certain criteria need
to be met for proper collection and transportation of urine
specimens. This ensures proper stability of the specimen and
accurate test results. The type of urine collection container cups
deployed by Solstas has a screw on lid....
Read
More
-
Solstas Lab Partners is pleased to announce the introduction of
new, highly-automated Sysmex hematology testing equipment at our
Greensboro, N.C., core reference laboratory. These new FDA cleared
hematology analyzers provide the latest in clinical hematology
testing capabilities for your patients....
Read
More
-
In association with the recent installation and validation of
new liquid chromatography/tandem mass spectrometry (LC/MSMS)
laboratory testing equipment, the Solstas Lab Partners Toxicology
Department has recently introduced lower analytical cutoffs for
detection and confirmation of common drugs of abuse. These lower
analytical cutoffs may provide improved clinical information for
the assessment of the patient status and correlation of immunoassay
screening and confirmation test results....
Read More
-
Respiratory viral infections represent one of the most common
human infections and are responsible for a range of diseases
including the common cold and pneumonia. Rapid diagnosis of
respiratory infections enables health care providers to begin
appropriate treatment, avoid unnecessary antibiotic use and
laboratory tests, and control nosocomial spread of these
infections....
Read
More
-
Solstas Lab Partners is providing this Client Notification
following recent information concerning new Centers for Disease
Control and Prevention (CDC) guidelines for blood lead
concentration in children....
Read More
-
Solstas Lab Partners is pleased to announce the commercial
availability of a new 4th generation human immunodeficiency virus
(HIV) qualitative test for the presence of HIV antigen and
antibodies....
Read More
-
Solstas Lab Partners is pleased to announce the addition to our
testing menu of the first FDA-cleared multiplexed nucleic acid test
(NAT) that can simultaneously detect 11 common viral, bacterial,
and parasitic causes of infectious gastroenteritis from a single
patient sample (Gastrointestinal Pathogen Panel (GPP))....
Read More
-
Solstas Lab Partners would like to draw your attention to a
specimen processing and transport change for the PLAC test -
Solstas test Code 23254. Please read the instructions below
carefully and refer any questions to our Client Services Department
at 1-888-664-7601....
Read More
-
Solstas Lab Partners is pleased to announce the availability and
change of the conventional microbiology collection swab to the
eSwab collection and transport system....
Read More
-
Shiga toxin--producing E.coli (STEC) causes approximately
100,000 illnesses, 3,000 hospitalizations, and 90 deaths annually
in the United States. Most reported STEC infections in the United
States are caused by E.coli O157:H7, with an estimated 73,000 cases
occurring each year. Non-O157 STEC bacteria also are important
causes of diarrheal illness in the United States;...
Read More
-
Solstas Lab Partners is pleased to announce the availability of
the QuantiFERON -TB Gold Interferon Gamma Release Assay (IGRA) for
the detection of Mycobacterium tuberculosis (MTB) reactivity. The
test will be performed at the Greensboro, N.C., reference
laboratory and reported within 3 days of specimen receipt. We are
pleased to offer this advanced test for MTB exposure screening that
provides an alternative to the conventional purified protein (PPD)
skin test....
Read More
-
Effective Jan 1, 2013 Solstas STAT testing facilities will adopt
the following Corporate Reference Ranges and Critical and Alert
Values...
Read More
-
Effective November 26, 2012, Solstas Lab Partners announced the
availability of testing for methylmalonic acid (MMA) at our
Greensboro, NC reference laboratory. This testing will be performed
by liquid chromatography-tandem mass spectrometry (LC-MS/MS) to
assist in the assessment of patients with signs and symptoms
associated with cobalamin (Vitamin B12) deficiency leading to
methylmalonic acidemia. Several studies have suggested that the
determination of serum or urinary methylmalonic acid may be a more
reliable marker of cobalamin deficiency than direct cobalamin
determination....
Read
More
-
Solstas Lab Partners is pleased to announce the introduction of
new liquid chromatographytandem mass spectrometry equipment that
enables some of the most advanced toxicology testing possible in
our toxicology departments. This improved clinical laboratory
testing technology now provides improved analytical sensitivity and
allows lower cutoffs to be used for drug screening. Effective
November 26, 2012, Solstas will enhance our Prescription Management
Program (PMP) by revising some of the drug of abuse testing cutoffs
to improved, lower detection limits....
Read More
-
Vaginitis is an inflammation of the vagina, and can affect women
of all ages. Vaginitis symptoms and treatment differ depending on
the causative agent: bacteria, the protozoan parasite Trichomonas
vaginalis, yeast, an allergen, or a decrease in estrogen. Of the
millions of cases of vaginitis each year, most are caused by
bacterial vaginosis (about 40% to 50%), followed by yeast
infections (20% to 25%) and then trichomoniasis (15% to
20%)....
Read More
-
Solstas Lab Partners is pleased to announce the addition of
NT-proBNP (Brain Natriuretic Peptide) to our clinical testing menu.
NT-proBNP may provide additional clinical information in the
diagnosis and evaluation of patients suspected of having congestive
heart failure. NT-proBNP has also been described in the risk
stratification of patients with acute coronary syndrome and as an
aid in the assessment of increased risk of cardiovascular events
and mortality in patients at risk for heart failure who have stable
coronary artery disease....
Read More
-
Effective October 1, 2012, Solstas Lab Partners® implemented the
following changes in two cardiovascular laboratory tests...
Read
More
-
Solstas Lab Partners®is pleased to announce that the algorithm
that is being used for the calculation of eGFR (estimated
Glomerular Filtration Rate) for the assessment of asymptomatic
chronic kidney disease was updated to the newer CKD-EPI (Chronic
Kidney Disease-Epidemiology Collaboration) equation, effective
October 15, 2012....
Read
More
-
Solstas Lab Partners and North Carolina Health Information
Exchange (NC HIE) have agreed to collaborate on the state's first
laboratory-supported health information exchange. ...
Read More
-
The three regional facilities give Solstas a significant launch
pad for growth throughout the Southeast. ...
Read More